Chimeric antigen receptor T-cell therapy in acute myeloid leukemia.

ABSTRACT:

Purpose of review

Treatment outcome of relapsed or refractory AML patients remains dismal and new treatment options are needed. Adoptive cell therapy using CAR-T cells is a potentially interesting approach in this.

Recent findings

Several potentially interesting AML targets are being investigated with CAR-T therapy with over 60 clinical trials listed on clinicaltrials.gov. The first clinical data are only just emerging with mixed results, once more proving that further research is needed.

Summary

Adoptive cell therapy using chimeric antigen receptor T cells is being investigated in AML through many clinical trials. So far, no AML-specific antigen has been identified, requiring additional strategies to mitigate on-target off-tumor toxicity and to increase efficacy. Foc

SUBMITTER: Koedam J 

PROVIDER: S-EPMC8815830 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature